# Pomalidomide

Source: https://onco.cc/drugs/pomalidomide/  
OnCo record `pomalidomide` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The third-generation thalidomide analogue for myeloma that has failed lenalidomide, and since 2020 the first new drug for Kaposi sarcoma in two decades.

## Summary

Pomalidomide, the third-generation thalidomide analogue, binds cereblon to trigger degradation of IKZF1 and IKZF3, giving direct anti-myeloma, immunostimulatory and anti-angiogenic effects that persist after lenalidomide failure. MM-003 (2013) showed an overall survival benefit versus high-dose dexamethasone in refractory myeloma, and US and EU approval followed in 2013 after at least two therapies including lenalidomide and a proteasome inhibitor. It anchors triplets such as isatuximab-Pd (ICARIA), elotuzumab-Pd and daratumumab-Pd (APOLLO). In 2020 it was approved for Kaposi sarcoma, both AIDS-related after antiretroviral failure and HIV-negative, on a 71% response rate, the first new Kaposi drug in two decades. Neutropenia and thrombosis risk need monitoring. Pomalidomide is the immunomodulator that keeps working after lenalidomide stops.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-08
- Tags: gap-fill
- Brand: Pomalyst / Imnovid
- Modality: Oral cereblon E3 ligase modulator (IMiD)
- Mechanism: Binds cereblon to induce degradation of IKZF1/3, with direct anti-myeloma, immunomodulatory and anti-angiogenic effects; active after lenalidomide failure.
- Approvals: US 2013: Multiple myeloma after ≥2 therapies including lenalidomide and a proteasome inhibitor; US 2020: Kaposi sarcoma (AIDS-related after ART failure; HIV-negative); EU 2013: Relapsed/refractory multiple myeloma

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Pomalidomide
- Label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=pomalidomide

## Connected records

- cancers: [HIV-associated (AIDS-related) lymphomas](https://onco.cc/cancers/hiv-associated-lymphoma/), [Kaposi sarcoma](https://onco.cc/cancers/kaposi-sarcoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Plasma cell leukaemia](https://onco.cc/cancers/plasma-cell-leukaemia/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [Cereblon (CRBN)](https://onco.cc/targets/cereblon/), [IKZF1 (Ikaros)](https://onco.cc/targets/ikzf1/), [IKZF3 (Aiolos)](https://onco.cc/targets/ikzf3/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Natco Pharma](https://onco.cc/companies/natco/)
- trials: [A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat](https://onco.cc/trials/nct04973605/), [A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)](https://onco.cc/trials/nct06464991/), [A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma](https://onco.cc/trials/nct06413498/), [A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela](https://onco.cc/trials/nct07391657/), [A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi](https://onco.cc/trials/nct05455320/), [A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez](https://onco.cc/trials/nct06208150/), [A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With](https://onco.cc/trials/nct05572515/), [A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) ](https://onco.cc/trials/nct03539744/), [A Study of Daratumumab](https://onco.cc/trials/nct05438043/), [A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07312188/), [A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide](https://onco.cc/trials/nct03151811/), [A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)](https://onco.cc/trials/nct07742215/), [A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ](https://onco.cc/trials/nct06953960/), [A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re](https://onco.cc/trials/nct05519085/), [A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult](https://onco.cc/trials/nct07227311/), [A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme](https://onco.cc/trials/nct05714839/), [A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments](https://onco.cc/trials/nct05020236/), [A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re](https://onco.cc/trials/nct05730036/), [All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo](https://onco.cc/trials/nct06956170/), [AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma](https://onco.cc/trials/nct06106945/), [MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other](https://onco.cc/trials/nct06152575/), [Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma](https://onco.cc/trials/nct07018050/), [Selinexor and Backbone Treatments of Multiple Myeloma Patients](https://onco.cc/trials/nct02343042/), [Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto](https://onco.cc/trials/nct06158841/), [Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies](https://onco.cc/trials/nct04068597/), [Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi](https://onco.cc/trials/nct07150104/)
- key papers: [CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy](https://onco.cc/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/)
- terms: [HHV-8 (KSHV) status and LANA-1 immunohistochemistry](https://onco.cc/terms/hhv8-kshv/), [Immunomodulatory drugs (IMiDs) and CELMoDs](https://onco.cc/terms/imid/)
- pathways: [Ubiquitin-proteasome system & protein homeostasis](https://onco.cc/pathways/ubiquitin-proteasome-system/)

---
JSON: https://onco.cc/api/v1/entities/pomalidomide.json